All In Biotech

Drug Trial Radar · NCT00269893

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)

Last checked: Nov 20, 2026Latest source record: Jun 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,038 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,038

Actual

Start

Nov 1991

Primary completion

Nov 1992

Study completion Nov 1992

Sponsor

Lead sponsor
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and safety of abciximab (an anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.

Conditions

  • Angina, Unstable
  • Angioplasty, Transluminal, Percutaneous Coronary

Interventions

  • AbciximabDrug

    0.25 mg/kg of body weight of abciximab either bolus or infusion.

  • PlaceboDrug

    Matching Placebo soulution either bolus or infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Any of the following within 30 days: Death from any cause; Myocardial infarction; Recurrent ischemic event requiring urgent intervention (repeat angioplasty, coronary artery bypass surgery, intracoronary stent placement, or intra-aortic balloon pump).Time frame: 30 days after angioplasty

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.